Treatment for alcoholic liver disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,052,340.00
Award Year:
2011
Program:
SBIR
Phase:
Phase II
Contract:
2R44AA019876-02
Award Id:
n/a
Agency Tracking Number:
R44AA019876
Solicitation Year:
2011
Solicitation Topic Code:
NIAAA
Solicitation Number:
PA10-050
Small Business Information
51 Charles Lindbergh Blvd, Uniondale, NY, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
053129065
Principal Investigator:
BERT OEHLEN
(516) 326-1200
boehlen@angion.com
Business Contact:
BERT OEHLEN
(516) 326-1200
boehlen@angion.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of liver cirrhosis in Western countries. Alcoholic liver disease can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Although several pharmacological therapies have been tried in patients with alcoholic liver disease, none of the therapeutics so far hasshown consistent improvement in the course of alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that modulators of endogenous ATRA levels have anti-fibrotic activity in mice. We have identified a novel series of ATRA modulators with excellent in vitro and in vivo pharmacological properties and demonstrate its anti-fibrotic activity in vivo. We propose to pursue the lead compound from this series towards an IND nomination as a potential therapeutic for alcoholic liver disease. PUBLIC HEALTH RELEVANCE: Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver caused by sustained immoderate alcohol consumption. Over time it frequently progresses to cirrhosis, an end- stage lethal disease which is the seventh leading cause of death in the United States and afflicts hundreds of millions of people worldwide. There is no therapeutic that shows consistent improvement in the courseof alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that modulators of endogenous ATRA levels have anti-fibrotic activity in mice and that we have identified a novel, in vivo efficacious, series of ATRA modulators. We propose to pursue the lead compound from this series towards an IND nomination as a potential therapeutic for alcoholic liver disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government